As­traZeneca lines up com­pe­ti­tion with Mer­ck in lung can­cer be­fore and af­ter surgery: #AACR23

OR­LAN­DO — As­traZeneca post­ed event-free sur­vival da­ta on Imfinzi’s use be­fore and af­ter surgery in pa­tients with non-small cell lung can­cer on Sun­day, with its ri­val Mer­ck months away from an FDA de­ci­sion in the same in­di­ca­tion.

In the study, pa­tients got Imfinzi plus chemother­a­py be­fore surgery and Imfinzi af­ter, or re­ceived on­ly chemother­a­py be­fore surgery. The tri­al’s pri­ma­ry end­points were event-free sur­vival and patho­log­i­cal com­plete re­sponse.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER